Analyzing Ayala Pharmaceuticals (NASDAQ:ADXS) and Bio-Path (NASDAQ:BPTH)

Insider and Institutional Ownership

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ayala Pharmaceuticals and Bio-Path’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

Valuation and Earnings

This table compares Ayala Pharmaceuticals and Bio-Path”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24 million	11.05	-$48.07 million	($5.02)	-0.12
Bio-Path	N/A	N/A	-$16.08 million	($1.09)	-0.03

Bio-Path has lower revenue, but higher earnings than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.51, suggesting that its share price is 151% less volatile than the S&P 500.

Summary

Ayala Pharmaceuticals beats Bio-Path on 5 of the 9 factors compared between the two stocks.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.